Chen, Fei
- Stony Brook University · Pathology (NIH department code)
- Broad Institute, Inc. (no department on record)
From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.
FY2023 NIH rank #9,573
- R01 Holder
- Long-Funded
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2009 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
FY2023 award categories
- Pathology
NIH Funding · FY2023
Linked Award Amount
$1M
Full award amounts, FY2023
Award Records
2
Records listing this PI
Award-Linked Rank
#9,573
By linked amount among FY2023 PIs
Earliest Year Loaded
2009
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2023 award records by amount
NIH award records listing Chen, Fei as a PI. Multi-PI records show the full award amount for context.
- 1R01CA276865-01R01Contact PISpatial genomic tools to interrogate T cell clonotypes, tumor clones and the microenvironment$691.3Kaward amount
- 5R01ES031822-04R01Contact PIDissecting Nrf2-dependent HIF1a activation mechanism in arsenic-induced cancer stem-like cellsStony Brook University · Pathology (NIH department code)$355.5Kaward amount
Award organizations
Organizations that administered FY2023 awards listing Chen, Fei as a PI.
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2009First NIH AwardBroad Institute, Inc.
- 2010$500K Cumulative Funding
- 2010Multi-Institutional ResearchAwards at 2 institutions
- 2012$1M Cumulative Funding
- 2013$2M Cumulative Funding
- 2014R01 Grant Holder
- 2017Entered Top 50% NationallyRanked #9501
- 2018$5M Cumulative Funding
- 2019Entered Top 25% NationallyRanked #1102
- 2019Entered Top 10% NationallyRanked #1102
- 2021$10M Cumulative Funding